7 recruiting, 2 active not recruiting, 2 not yet recruiting, 1 completed. 6 Phase 3, 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 2, Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 5 | Recruiting 5 |
| Phase 1 | 4 | Recruiting 3, Completed 1 |
Follow Rescue Medications: new trials by email Literature Review of Rescue Medications trials Research Report on Rescue Medications
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) Gocatamig, Durvalumab, Rescue Medications - Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 564 | 2026-12-07 | 2026-11-02 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-20 | 2026-09-21 |
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan - Lung Neoplasm Malignant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-30 | 2026-10-01 |
| A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Sacituzumab tirumotecan, Bevacizumab, Rescue Medications - Ovarian Neoplasms, Ovarian Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 900 | 2026-02-16 | 2026-10-13 |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Gocatamig, I-DXd, Atezolizumab - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 170 | 2026-01-29 | 2026-10-20 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab - Cervical Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1023 | 2026-01-19 | 2026-10-29 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) R-DXD, I-DXD, Docetaxel - Lung Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 144 | 2025-05-28 | 2026-10-07 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 210 | 2024-08-07 | 2026-09-03 |
| A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) MK-6837, Pembrolizumab, Rescue Medications - Neoplasm Metastasis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 40 | 2024-07-14 | 2026-08-28 |
| A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan - Gastroesophageal Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 473 | 2024-05-03 | 2026-10-22 |
| Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Sacituzumab tirumotecan, Doxorubicin, Paclitaxel - Endometrial Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 710 | 2023-12-06 | 2026-08-28 |
Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Lung Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
United States (10) · Chile (9) · Germany (8) · Israel (8) · Italy (8) · Spain (8) · Brazil (7) · South Korea (7) · Canada (6) · China (6) · Greece (6) · Poland (6) · Argentina (5) · France (5) · Taiwan (5)
2023 (4), 2025 (2)